Cingulate (CING) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed Zhengye Biotechnology (ZYBT) over the past year, gaining 27.8% versus a loss of 30.8%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $67.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | ZYBT |
|---|---|---|
| Share price | $4.51 | $1.48 |
| Market cap | $67.48M | $70.14M |
| 1-day change | -14.26% | -2.63% |
| YTD return | +3.92% | +28.70% |
| 1-year return | +27.76% | -30.84% |
| EPS (TTM) | $-2.67 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.64M |
| Revenue growth (YoY) | — | -34.83% |
| Net income (latest FY) | $-22.45M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | — | -60.60% |
| Net margin | — | -59.99% |
| 52-week high | $11.89 | $8.01 |
| 52-week low | $3.16 | $0.616 |
| Distance from 52-week high | -62.07% | -81.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +370.07% | — |
| Average volume | 178.82K | 569.22K |
| Shares outstanding | 14.96M | 47.39M |
| Employees | 14 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed ZYBT by 58.6 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
CING vs ZYBT FAQ
Which is bigger, Cingulate or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $67.48M for Cingulate (CING).
Which stock has performed better over the past year, CING or ZYBT?
CING returned +27.76% over the past 12 months, compared with -30.84% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.